In the normal prostate, the expression of PXR turned out to be the highest in the stratum basale; at earlier stages of the disease, PXR immunoreactivity is higher in prostate tumor tissues than in normal tissues, whereas with progression to later stages, the PXR expression tends to decline [351]. This evidence concerns the gene NR1I2 and prostate neoplasm.